ArticleNature medicine2026
AI-based characterization of Alzheimer's disease phenotypes from population-scale single-cell data.
Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
The complexity of Alzheimer's disease (AD) manifests in diverse clinical phenotypes, including cognitive impairment and neuropsychiatric symptoms. However, the etiology of these phenotypes remains elusive. To address this, the PsychAD project generated a population-level single-nucleus RNA sequencing dataset comprising over 6 million nuclei from the prefrontal cortex of >1,000 individual brains, covering a variety of disease phenotypes. Here, leveraging this dataset, we developed a computational framework, called Phenotype Associated Single Cell encoder (PASCode), to score single-cell phenotype associations, and identified ∼1.5 million phenotype-associated cells (PACs) from 584 donors with AD-related phenotypes. PASCode ensembles multiple statistical methods into a graph neural model for robust scoring. Comparing PACs within 27 brain cell subclasses, we prioritized cell subpopulations and their expressed genes for various AD phenotypes. For instance, we identified microglia subpopulations implicated in AD pathology; reactive astrocyte subtypes with altered neuroprotective and neurotoxic gene expression that likely confer cognitive resilience; and enhanced excitatory/inhibitory imbalance and mitochondrial dysfunction in cognitively impaired AD donors. We also identified many PACs for multiple phenotypes, including the astrocytes between AD and depression showing specific gene expression patterns such as inflammation and endoplasmic reticulum stress pathways. These prioritized subpopulations, genes and pathways potentially offer valuable insights for precision diagnostic and therapeutic development. We also validated our findings in external population-scale datasets including AD and major depressive disorder, compiled an AD-phenotypic single-cell atlas and delivered the framework as an open-source tool with pre-trained models and a web application for community use.
Identifiers
42778763What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.